Zusammenfassung
Die wesentlichen Therapieoptionen beim Nierenzellkarzinom sind Chirurgie und Immuntherapie. Die Chirurgie geht allerdings mit einer erheblichen perioperativen Immundysfunktion einher. Diese Immundysfunktion kann durch eine Vorbehandlung mit Interleukin-2 (IL-2) moduliert werden, was das tumorspezifische Überleben zu verbessern scheint. Die perioperative Immunmodulation könnte die therapeutische Lücke zwischen neoadjuvanter und adjuvanter Immuntherapie schließen. In diesem Artikel wird die verfügbare Literatur kritisch gesichtet und eigene Originaldaten an 63 Patienten präsentiert.
Abstract
Surgery and immunotherapy are the mainstay in the treatment of renal cell carcinoma. Surgery, however, is associated with considerable perioperative immunodysfunction. This immunodysfunction can be modulated by pretreatment with Interleukin-2 (IL-2), which appears to prolong tumour-specific survival. Perioperative immunomodulation could help close the therapeutic gap between neoadjuvant and adjuvant immunotherapy. This article reviews recent literature and presents original data of 63 patients.
Schlüsselwörter
Immunmodulation - perioperativ - Interleukin-2 - Nierentumor
Key words
Immunomodulation - perioperative - interleukin-2 - renal cancer
Literatur
-
1
Hermanek P, Schrott K M.
Evaluation of the new tumor, nodes and metastasis classification of renal cell carcinoma.
J Urol.
1990;
144
238-242
-
2
Carl P, Klein U, Gebauer A, Schmiedt E.
The value of lymphography for the TNM classification of renal carcinoma.
Eur Urol.
1977;
3
286-288
-
3
Giuliani L, Giberti C, Martorana G, Rovida S.
Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors.
J Urol.
1990;
143
468-474
-
4
Sánchez de la Muela P, Zudaire J J, Robles J E, Rosell D, Aguera L, De Castro F, Isa W, Berián J M.
Renal cell carcinoma: vena caval invasion and prognostic factors.
Eur Urol.
1991;
19
284-290
-
5
Herrlinger A, Schrott K M, Schott G, Sigel A.
What are the benefits of extended dissection of the regional lymph nodes in the therapy of renal cell carcinoma?.
J Urol.
1991;
146
1224-1227
-
6
Eschwege P, Saussine C, Steichen G, Delepaul B, Drelon L, Jacqmin D.
Radical nephrectomy for renal cell carcinoma 30 mm or less: long-term follow results.
J Urol.
1996;
155
1196-1199
-
7
Takashi M, Takagi Y, Sakata T, Shimoji T, Miyake K.
Clinicopathological characteristics of small renal cell carcinomas.
Int Urol Nephrol.
1994;
26
621-629
-
8
Siminovitch J P, Montie J E, Straffon R A.
Lymphadenectomy in renal adenocarcinoma.
J Urol.
1982;
127
1090-1091
-
9
Hultén L, Rosencrantz M, Seeman T, Wahlqvist L, Åhrén C.
Occurrence and localization of lymph node metastases in renal carcinoma.
Scand J Urol Nephrol.
1969;
3
129-133
-
10
Robson C J, Churchill B M, Anderson W.
The results of radical nephrectomy for renal cell carcinoma.
J Urol.
1969;
101
297-301
-
11
Parry-Billings M, Baigrie R J, Lamont P M, Morris P J, Newsholme E A.
Effects of major and minor surgery on plasma glutamine and cytokine levels.
Arch Surg.
1992;
127
1237-1240
-
12
Hensler T, Hecker H, Heeg K, Heidecke C-D, Bartels H, Barthlen W, Wagner H, Siewert J R, Holzmann B.
Distinct mechanisms of immunosuppression as a consequence of major surgery.
Infect Immun.
1997;
65
2283-2291
-
13
Allendorf J D, Bessler M, Whelan R L, Trokel M, Laird D A, Terry M B, Treat M R.
Postoperative immune function varies inversely with the degree of surgical trauma in a murine model.
Surg Endosc.
1997;
11
427-430
-
14
Kuntz C, Wunsch A, Bay F, Windeler J, Glaser F, Herfarth C.
Prospective randomized study of stress and immune response after laparoscopic vs. conventional colonic resection.
Surg Endosc.
1998;
12
963-967
-
15
Gitzelmann C A, Mendoza-Sagaon M, Talamini M A, Ahmad S A, Pegoli W J, Paidas C N.
Cell-mediated immune response is better preserved by laparoscopy than laparotomy.
Surgery.
2000;
127
65-71
-
16
Ogawa K, Hirai M, Katsube T, Murayama M, Hamaguchi K, Shimakawa T, Naritake Y, Hosokawa T, Kajiwara T.
Suppression of cellular immunity by surgical stress.
Surgery.
2000;
127
329-336
-
17
Leaver H A, Craig S R, Yap P L, Walker W S.
Lymphocyte responses following open and minimally invasive thoracic surgery.
Eur J Clin Invest.
2000;
30
230-238
-
18
Böhm M, Ittenson A, Philipp C, Röhl F-W, Ansorge S, Allhoff E P.
Complex perioperative immunodysfunction in patients with renal cell carcinoma.
J Urol.
2001;
166
831-836
-
19
Ashida S, Okuda H, Chikazawa M, Tanimura M, Sugita O, Yamamoto Y, Nakamura S, Moriyama M, Shuin T.
Detection of circulating cancer cells with von Hippel-Lindau gene mutation in peripheral blood of patients with renal cell carcinoma.
Clin Cancer Res.
2000;
6
3817-3822
-
20
McKiernan J M, Buttyan R, Bander N H, de-la-Taille A, Stifelman M D, Emanuel E R, Bagiella E, Rubin M A, Katz A E, Olsson C A, Sawczuk I S.
The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9.
Cancer.
1999;
86
492-497
-
21
Bilkenroth U, Taubert H, Riemann D, Rebmann U, Heynemann H, Meye A.
Detection and enrichment of disseminated renal carcinoma cells from peripheral blood by immunogenetic cell separation.
Int J Cancer.
2001;
92
577-582
-
22 Thèze J. The cytokine network and immune functions. New York: Oxford University Press 1999
-
23
Mocellin S, Wang E, Marincola F M.
Cytokines and immune response in the tumor microenvironment.
J Immunther.
2001;
24
392-407
-
24 Abbas A K, Lichtman A H, Pober J S. Cellular and molecular immunology. Philadelphia: Saunders 2000
-
25 Smith K A. IL-2. In: Oppenheim JJ, Feldman M (Hrsg.). Cytokine reference. London: Academic Press 2001: 113-126
-
26
Civallero M, Barni S, Nano R, Capelli E.
Dendritic cells and interleukin-2: cytochemical and ultrastructural study.
Histol Histopathol.
2000;
15
1077-1085
-
27
Schnurr M, Galambos P, Scholz C, Dauer M, Krug A, Hartmann G, Eigler A, Endres S.
Deutsches Ärzteblatt .
2002;
99
A2408-A2416
-
28
Overwijk W W, Theoret M R, Restifo N P.
The future of Interleukin-2: enhancing therapeutic anticancer vaccines.
Cancer J Sci AM.
2000;
6 Suppl 1
S76-S80
-
29
Hoffman D M, Figlin R A.
Intratumoral interleukin-2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex.
World J Urol.
2000;
18
152-156
-
30
Larchian W A, Horiguchi Y, Nair S K, Fair W R, Heston W D, Gilboa E.
Effectiveness of combined Interleukin-2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer.
Clin Cancer Res.
2000;
6
2913-2920
-
31
Dudley M E, Wunderlich J R, Robbins P F, Yang J C, Hwu P, Schwartzentruber D J, Topalian S L, Sherry R, Restifo N P, Hubicki A M, Robinson M R, Raffeld M, Duray P, Seipp C A, Rogers-Freezer L, Morton K E, Mavroukakis S A, White D E, Rosenberg S A.
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes.
Science.
2002;
298
850-854
-
32
Holden S A, Lan Y, Pardo A M, Wesolowski J S, Gillies S D.
Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents.
Clin Cancer Res.
2001;
7
2862-2869
-
33
Nichols P H, Ramsden C W, Ward U, Sedman P C, Primrose J N.
Perioperative immunotherapy with recombinant interleukin 2 in patients undergoing surgery for colorectal cancer.
Cancer Res.
1992;
52
5765-5769
-
34
Nichols P H, Ramsden C W, Ward U, Trejdosiewicz L K, Ambrose N S, Primrose J N.
Perioperative modulation of cellular immunity in patients with colorectal cancer.
Clin Exp Immunol.
1993;
94
4-10
-
35
Deehan D J, Heys S D, Simpson W, Broom J, McMillan D N, Eremin O.
Modulation of the cytokine and acute-phase response to major surgery by recombinant interleukin-2.
Br J Surg.
1995;
82
86-90
-
36
Böhm M, Ittenson A, Schierbaum K F, Röhl F-W, Ansorge S, Allhoff E P.
Petreatment with interleukin-2 (IL-2) attenuates perioperative immunodysfunction in patients with renal cell carcinoma.
Eur Urol.
2002;
41
458-468
-
37
Brivio F, Lissoni P, Alderi G, Barni S, Lavorato F, Fumagalli L.
Preoperative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advances colorectal cancer patients.
Oncology.
1996;
53
263-268
-
38 Brivio F, Brivio O, Lissoni P, Emanuelli G, Girlando M, Uggeri F. Presurgical neuroimmunotherapy with melatonin and interleukin-2 in cancer patients. In: Maestroni GJM, Conti A, Reiter RJ (Hrsg.). Therapeutic potential of melatonin. Front Horm Res. Basel: Karger 1997: 137-148
-
39
Masotti A, Morandini G, Ortolani R, Fumagalli L.
Phase-II randomized study of preoperative IL-2 administration in operable NSCLC.
Lung Cancer.
1998;
20
191-202
-
40 De Maeyer E, De Maeyer-Guignard J. Type I interferons. In: Bona CA, Revillard J-P (Hrsg.). Cytokines and cytokine receptors: physiology and pathological disorders. Amsterdam: Harwood Academic Publishers 2000: 316-333
-
41
Luft T, Pang K C, Thomas E, Hertzog P, Hart D N, Trapani J, Cebon J.
Type I IFNs enhance the terminal differentiation of dendritic cells.
J Immunol.
1998;
161
1947-1953
-
42
Sedman P C, Ramsden C W, Brennan T G, Giles G R, Guillou P J.
Effects of low dose perioperative interferon on the surgically induced suppression of antitumour immune responses.
Br J Surg.
1988;
75
976-981
-
43
Fujioka T, Yoshida N, Hasegawa M, Ishikura K, Suzuki Y, Kubo T.
Interleukin-2 expanded tumor-infiltrating lymphocytes and their response to preoperative α-interferon in patients with renal cell carcinoma.
J Urol.
1994;
152
852-856
-
44
Houvenaeghel G, Bladou F, Blache J L, Olive D, Monges D, Jacquemier J, Chaudet H, Delpero J R, Guerinel G.
Tolerance and feasibility of perioperative treatment with interferon-α2a in advanced cancers.
Int Surg.
1997;
82
165-169
-
45
Sejima T, Miyagawa I.
The evaluation of Fas/Fas ligand system in renal cell carcinoma - the effect of preoperative interferon-α therapy.
Nippon Hinyokika Gakkai Zasshi.
1999;
90
826-832
-
46
Nielsen H J, Pedersen B K, Moesgaard F, Haahr P M, Kehlet H.
Effect of ranitidine on postoperative suppression of natural killer cell activity and delayed hypersensitivity.
Acta Chir Scand.
1989;
155
377-382
-
47
Katoh J, Tsuchiya K, Osawa H, Sato W, Matsumura G, Iida Y, Suzuki S, Hosaka S, Yoshii S, Tada Y.
Cimetidine reduces impairment of cellular immunity after cardiac operations with cardiopulmonary bypass.
J Thorac Cardiovasc Surg.
1998;
116
312-318
-
48
O'Riordain M G, Fearon K C, Ross J A, Rogers P, Falconer J S, Bartolo D C, Garden O J, Carter D C.
Glutamine-supplemented total parenteral nutrition enhances T-lymphocyte response in surgical patients undergoing colorectal resection.
Ann Surg.
1994;
220
212-221
-
49
Kerrebijn J D, Simons P J, Balm A J, Tas M, Knegt P P, de Vries N, Tan I B, Drexhage H A.
Thymostimulin enhancement of T-cell infiltration into head and neck squamous cell carcinoma.
Head Neck.
1996;
18
335-342
-
50
Hamano K, Gohra H, Katoh T, Fujimura Y, Zempo N, Esato K.
The preoperative administration of lentinan ameliorated the impairment of natural killer activity after cardiopulmonary bypass.
Int J Immunopharmacol.
1999;
21
531-540
-
51
Hubel K, Mansmann G, Schafer H, Oberhauser F, Diehl V, Engert A.
Increase of antiinflammatory cytokines in patients with esophageal cancer after perioperative treatment with G-CSF.
Cytokine.
2000;
12
1797-1800
-
52
Bex A, Horenblas S, Meinhardt W, Verra N, de Gast G C.
The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ.
Eur Urol.
2002;
42
570-576
-
53
Morris K T, Johnson N, Homer L, Walts D.
A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites.
Am J Surg.
2000;
179
407-411
-
54
Oz M C, Whitworth G C, Liu E H.
Complementary medicine in the surgical wards.
JAMA.
1998;
279
710-711
-
55
Fair W R.
Back to the future - the role of complementary medicine in urology.
J Urol.
1999;
162
411-420
-
56 Bruss K, Salter C, Galán E. American Cancer Society's guide to complementary and alternative cancer methods. Atlanta: American Cancer Society 2000
PD Dr. med. Malte Böhm
Urologische Klinik · Otto-von-Guericke Universität
Leipziger Str. 44
39120 Magdeburg
Phone: 0391-67-15036
Fax: 0391-67-15094
Email: malte.boehm@medizin.uni-magdeburg.de
